Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CSCI Stock Forecast 2026-2027
$2.03
Current Price
$6.74M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CSCI Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CSCI Price Momentum
-2.9%
1 Week Change
+157.0%
1 Month Change
-28.3%
1 Year Change
-1.5%
Year-to-Date Change
-53.9%
From 52W High of $4.40
+157.0%
From 52W Low of $0.79
📊 TOP ANALYST CALLS
Did CSCI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cosciens Biopharma is one of their latest high-conviction picks.
Latest CSCI Stock Price Targets & Analyst Predictions
CSCI has shown a year-to-date change of -1.5% and a 1-year change of -28.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CSCI. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CSCI Analyst Ratings
0
Buy
0
Hold
0
Sell
CSCI Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $2.03
Latest CSCI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CSCI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $15.00 |
| Aug 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Jul 14, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| May 12, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Apr 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Mar 28, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $28.00 |
| Mar 30, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $1.50 |
| Oct 25, 2021 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Nov 9, 2015 | Canaccord Genuity | Buy | Upgrade | $N/A | |
| Apr 14, 2015 | H.C. Wainwright | Buy | Upgrade | $N/A | |
| Jul 17, 2014 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Jul 25, 2013 | Euro Pacific Capital | Hold | Initiates | $N/A | |
| Jan 3, 2013 | McNicoll Lewis Vlak | Buy | Upgrade | $N/A | |
| Dec 31, 2012 | Canaccord Genuity | Hold | Maintains | $2.50 | |
| Oct 12, 2012 | Bloom Burton & Co. | Sell | Maintains | $2.00 |
Cosciens Biopharma Inc. (CSCI) Competitors
The following stocks are similar to Cosciens Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CSCI
Cosciens Biopharma
mkt cap
6.74M
Cosciens Biopharma Inc. (CSCI) Financial Data
Cosciens Biopharma Inc. has a market capitalization of $6.74M with a P/E ratio of -0.3x. The company generates $9.59M in trailing twelve-month revenue with a 49.3% profit margin.
Revenue growth is +83.3% quarter-over-quarter, while maintaining an operating margin of -157.5% and return on equity of -116.3%.
Valuation Metrics
Market Cap
$6.74M
Enterprise Value
$-7,346,620
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
+83.3%
Gross Margin
+35.4%
Operating Margin
-157.5%
Net Margin
+49.3%
EPS Growth
+17.6%
Financial Health
Cash/Price Ratio
N/A
Current Ratio
3.0x
Debt/Equity
0.3x
ROE
-116.3%
ROA
-43.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cosciens Biopharma Inc. (CSCI) Business Model
About Cosciens Biopharma Inc.
What They Do
Develops natural plant-based pharmaceutical products.
Business Model
COSCIENS Biopharma generates revenue by developing and commercializing natural active ingredients and pharmaceuticals through its Active Ingredients and Biopharmaceuticals segments. The company utilizes proprietary extraction technologies to supply key ingredients to major skincare brands and also focuses on creating nutraceuticals and pharmaceuticals that enhance health and wellness.
Additional Information
The company is notable for its FDA-approved product, Macimorelin, which serves as an oral diagnostic test for adult growth hormone deficiency. COSCIENS Biopharma's emphasis on innovation in plant-derived bioactives positions it uniquely in the health technology and pharmaceutical sectors, addressing growing consumer demand for natural and effective health solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
28
CEO
Mr. Peter Harry Puccetti CFA
Country
Canada
IPO Year
2000
Website
www.cosciensbio.comCosciens Biopharma Inc. (CSCI) Latest News & Analysis
Latest News
COSCIENS Provides Strategic Update
1 month ago
Quick Summary
COSCIENS Biopharma Inc. (TSX: CSCI) will cease funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, which are expected to enter structured insolvency soon.
Why It Matters
COSCIENS Biopharma's cessation of funding for its German subsidiaries signals potential financial distress, raising concerns over its stability and future profitability, impacting investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
COSCIENS Biopharma's subsidiary, Aeterna Zentaris, has signed an exclusive distribution agreement with Wuzhou Drug for Macrilen® in Hong Kong, Macao, Singapore, and Guangdong and Hainan provinces.
Why It Matters
The exclusive distribution agreement expands COSCIENS Biopharma's market reach for Macrilen®, potentially increasing revenue and market share in Asia, which could positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
COSCIENS Biopharma Inc. Announces Leadership Change
5 months ago
Quick Summary
COSCIENS Biopharma Inc. (TSX: CSCI) announced Peter H. Puccetti as Interim CEO, succeeding Anna Biehn, effective immediately.
Why It Matters
Leadership changes can signal strategic shifts or instability, impacting investor confidence and stock performance. Puccetti's interim role may influence the company's direction and operational focus.
Source: GlobeNewsWire
Market Sentiment:
Neutral
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
8 months ago
Quick Summary
COSCIENS Board approves a plan to voluntarily delist from Nasdaq but will retain its listing on the Toronto Stock Exchange (TSX).
Why It Matters
COSCIENS’ voluntary delisting from Nasdaq could impact liquidity and investor access, potentially affecting stock valuation and market perception while maintaining a presence on the TSX.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) held its annual general and special meeting on June 30, 2025, and announced the voting results on various business items.
Why It Matters
The voting results from COSCIENS' annual meeting can signal shareholder confidence and influence stock performance, impacting investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
COSCIENS Biopharma Inc. (NASDAQ: CSCI, TSX: CSCI) announced it received director nominations from Goodwood Fund and Puccetti Funds Management for its upcoming shareholder meeting.
Why It Matters
Director nominations can signal potential changes in company strategy or governance, impacting stock performance and investor sentiment regarding COSCIENS Biopharma's future direction.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CSCI Stock
What is Cosciens Biopharma Inc.'s (CSCI) stock forecast for 2026?
Analyst forecasts for Cosciens Biopharma Inc. (CSCI) are not currently available. The stock is trading at $2.03.
Is CSCI stock a good investment in 2026?
Analyst ratings for CSCI are not currently available. The stock is currently trading at $2.03. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CSCI stock?
Price predictions from Wall Street analysts for CSCI are not currently available. The stock is trading at $2.03.
What is Cosciens Biopharma Inc.'s business model?
COSCIENS Biopharma generates revenue by developing and commercializing natural active ingredients and pharmaceuticals through its Active Ingredients and Biopharmaceuticals segments. The company utilizes proprietary extraction technologies to supply key ingredients to major skincare brands and also focuses on creating nutraceuticals and pharmaceuticals that enhance health and wellness.
What is the highest forecasted price for CSCI Cosciens Biopharma Inc.?
Price targets from Wall Street analysts for CSCI are not currently available. The stock is trading at $2.03.
What is the lowest forecasted price for CSCI Cosciens Biopharma Inc.?
Price targets from Wall Street analysts for CSCI are not currently available. The stock is trading at $2.03.
What is the overall CSCI consensus from analysts for Cosciens Biopharma Inc.?
Analyst ratings for CSCI are not currently available. The stock is trading at $2.03.
How accurate are CSCI stock price projections?
Stock price projections, including those for Cosciens Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 2:33 AM UTC